Vivesto AB stock analysis
Vivesto AB (0N4A) Share Price & Analysis
0N4A Stock Chart & Stats
- Day’s Range
- SEK 15.80 - SEK 15.80
- 52-Week Range
- SEK 8.26 - SEK 20.54
- Previous Close
- SEK 15.80
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- SEK 79.05M
- Enterprise Value
- SEK 76.35M
- Total Cash (Recent Filing)
- SEK 23.51M
- Total Debt (Recent Filing)
- SEK 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.51
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Equity Cushion
A debt-free balance sheet and substantial equity cushion give Vivesto greater financial flexibility than a highly leveraged development-stage biotech. This can support continued research investment and help absorb operating losses, although preserving that cushion depends on improving operations or securing funding.
Improving Loss And Cash-burn Trend
The substantial reduction in operating cash burn from prior years indicates better cost control or a more focused operating base. While cash generation remains negative, continued improvement could extend liquidity and reduce the amount of external capital needed to advance the pipeline.
Focused Oncology Development Platform
A focused oncology strategy gives Vivesto a defined therapeutic area and the potential to create value through differentiated drug candidates or delivery technologies. If development succeeds, partnering or commercialization could provide milestone, royalty, or product revenue opportunities.
Bears Say
Near-zero Revenue Base
Near-zero reported revenue shows that Vivesto has not yet established a recurring commercial business capable of funding operations. Until a candidate is approved, partnered on meaningful terms, or commercialized, financial performance remains heavily dependent on development progress and available capital.
Persistent Negative Cash Generation
持续 negative operating and free cash flow means the company continues consuming liquidity while its pipeline is developed. This constrains investment flexibility and creates a durable need for financing or partnering, particularly if development expenses rise before revenue begins.
Ongoing Operating Losses
Material recurring losses indicate that Vivesto has not reached positive earnings or demonstrated a stable path to profitability in its reported results. Narrower losses are encouraging, but continued deficits can erode the equity base and increase dependence on future funding.
0N4A FAQ
What was Vivesto AB’s price range in the past 12 months?
What is Vivesto AB’s market cap?
When is Vivesto AB’s upcoming earnings report date?
How were Vivesto AB’s earnings last quarter?
Is Vivesto AB overvalued?
Does Vivesto AB pay dividends?
What is Vivesto AB’s EPS estimate?
How many shares outstanding does Vivesto AB have?
What happened to Vivesto AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vivesto AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Vivesto AB
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Erik Kinnman Assoc.
- Employees
- 4
- Website
- www.vivesto.com
- Address
- Gustav III:s Boulevard 46, Solna, 169 73, SE
Vivesto AB (0N4A) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 0 | 2 |
| Technical Analysis | 2 | 0 | 1 |
| Moving Averages | 11 | 0 | 1 |










